{Reference Type}: Journal Article
{Title}: Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma.
{Author}: Ohmura S;Grünewald TGP;
{Journal}: Clin Cancer Res
{Volume}: 30
{Issue}: 16
{Year}: 2024 Aug 15
{Factor}: 13.801
{DOI}: 10.1158/1078-0432.CCR-24-1047
{Abstract}: EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacologic ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, DNA repair, and translation machinery, which could maximize the therapeutic window of the combinatory therapy. See related article by Jess et al., p. 3533.